DOUGLAS, ISLE OF MAN / ACCESS Newswire / May 28, 2025 / Agronomics (LSE:ANIC), a leading listed company in the field of clean food, is delighted to announce that its portfolio company, Good Dog ...

Amgen's weight loss candidate reported mixed phase 2 data, but the company has other weapons. Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only ...

Meatly reduces bioreactor costs by 95% and medium costs to 1.5p/l at scale DOUGLAS, ISLE OF MAN / ACCESS Newswire / May 28, 2025 / Agronomics (LSE:ANIC), a leading listed company in the field of ...

The Global Single-use Bioreactors Market is set to witness a healthy growth rate of 20% by 2029. Technological innovations such as the launch of large-scale single-use bioreactors, demand from ...

In fact, Amgen’s overall revenue of $8.1 billion was a 9% increase year over year and topped the analyst consensus. The lack of success for the Horizon drugs is apparently becoming a sore ...

Teprotumumab approved as first targeted treatment for thyroid eye disease The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants. The historically tight-lipped Amgen execs remain judicious ...

RBC lowers Amgen price target to $320 but keeps Outperform rating based on steady outlook for MariTide. Goldman sees MariTide efficacy risk in Phase 3 trial due to dose escalation, possibly ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

Bioreactors have become irreplaceable tools in bioprocessing, revolutionizing the production of many biotechnological products. 1,2 They offer optimized and controlled environments to enhance cell ...

Amgen's diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, but ...